SCHEMBL23926008

SCHEMBL23926008

Cc1n[nH]c(C)c1C(=O)Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.57
DYRK1A Q13627 1/20 0.42
HCAR2 Q8TDS4 3/20 0.41
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GAA P10253 1/20 0.39
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
P2RX7 Q99572 5/20 0.34
CSNK2A2 P19784 2/20 0.33
KDR P35968 2/20 0.33
CSNK2B P67870 2/20 0.33
CSNK2A1 P68400 2/20 0.33
DAO P14920 1/20 0.33
KDM4E B2RXH2 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
AR P10275 1/20 0.33
CHEK1 O14757 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1640767 0.79 PDE4D (0.59) PDE4DDYRK1AHCAR2LMNAL3MBTL1
SCHEMBL1663754 0.79 PDE4D (0.59) PDE4DDYRK1AHCAR2LMNAL3MBTL1
SCHEMBL15777023 0.77 PDE4D (0.57) PDE4DDYRK1AHCAR2LMNAL3MBTL1
SCHEMBL10839267 0.77 PDE4D (0.56) PDE4DDYRK1AHCAR2LMNAL3MBTL1
SCHEMBL4754626 0.76 PDE4D (0.66) PDE4DDYRK1ALMNAL3MBTL1GAA
SCHEMBL31663080 0.75 PDE4D (0.42) PDE4DGAA
SCHEMBL8006591 0.74 PDE4D (0.53) PDE4DDYRK1AHCAR2LMNAL3MBTL1
SCHEMBL10858885 0.74 PDE4D (0.63) PDE4DDYRK1AHCAR2LMNAL3MBTL1
SCHEMBL352117 0.74 PDE4D (0.53) PDE4DDYRK1AHCAR2LMNAL3MBTL1
SCHEMBL5317321 0.74 PDE4D (0.37) PDE4DHCAR2GAAKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021211922-A1 SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN PRELUDE THERAPEUTICS, INCORPORATED (US) 2021-10-21 WO disclosed